212 results about "Cardiac functioning" patented technology

The invention provides a four-dimensional cardiac function imaging method and device based on a biological magnetic signal. The method comprises the following steps: acquiring a magnetocardiogram signal of a to-be-detected object and dynamic structure information of a target trunk part in a full cardiac cycle; wherein the target trunk part at least comprises double lungs, a trunk, a heart cavity of the trunk and a pericardium structure, and the dynamic structure information comprises a contour structure and a multi-frame dynamic image; performing spatial registration on the dynamic structure information and the sensor for acquiring the magnetocardiogram signal to obtain coordinates of the sensor in a coordinate system of the dynamic structure information; according to the dynamic structure information, the coordinate of the sensor and the magnetocardiogram signal, calculating and reconstructing cardiac electrical excitation activity to obtain a calculation and reconstruction result; and converting the calculation reconstruction result into a four-dimensional visual image. According to the method, heart magnetic imaging and heart movement are combined, on the basis of obtained dynamic structure information and heart magnetic signals, the characteristics of biological magnetic signals are fully utilized, and the signal processing technology is integrated through space registration, so that accurate reconstruction of four-dimensional representation of the heart and visual display of functional activities are realized; therefore, the obtained four-dimensional visual image can completely represent the dynamic electrophysiological activities of the whole heart (including epicardium, endocardium and intrawall tissues) in a cardiac cycle, and a technical scheme with different concepts is provided for non-invasive imaging of cardiac electrical excitation activities.

The invention discloses a convolutional neural network information processing method for heart function dynamic monitoring, and belongs to the technical field of medical detection and monitoring. Comprising the following steps that multi-mode electrocardiosignal data and current physiological state parameters of a patient are obtained, and initial configuration of the intelligent heart function monitoring device is obtained; determining the signal quality grade of each signal channel, and generating a dynamic filtering adjustment strategy of the multi-modal signal acquisition module; configuring a feature extraction strategy of a double-branch convolutional neural network module based on the signal features of the target analysis signal segment and the physiological state parameters; performing multi-scale time sequence feature extraction and frequency domain autonomic nerve regulation feature extraction on the target analysis signal segment by using a double-branch convolutional neural network module according to a feature extraction strategy; executing arrhythmia classification, heart rate variability parameter quantification, heart function evaluation grade and graded early warning tasks, and outputting multi-stage intelligent early warning information from normal monitoring, potential risk and abnormal early warning to an emergency state.

The systems, devices, and methods presented herein use a heart pump to obtain measurements of cardiovascular function. The heart pumps described herein can operate in parallel with and unload the heart. The system can quantify the functioning of the native heart by measuring certain parameters / signals such as pressure or motor current, then calculate and display one or more metrics of cardiovascular function. These metrics, such as left ventricular end diastolic pressure (LVEDP), left ventricular pressure, and contractility, provide valuable information to a user regarding a patient's state of heart function and recovery.

The invention discloses a cardiac function rehabilitation state monitoring method for coronary heart disease postoperative population. The method comprises the following steps: constructing a third-order dynamic baseline adaptive to postoperative pathological evolution; carrying out stress-physiological coupling modeling on the basis of a double-AI (Artificial Intelligence) collaborative architecture; and carrying out trend early warning of equal-condition longitudinal pairing. The heart function rehabilitation state monitoring system comprises an electrocardiosignal preprocessing unit, the electrocardiosignal preprocessing unit is connected with a multi-dimensional electrocardiosignal feature extraction unit, and the multi-dimensional electrocardiosignal feature extraction unit is connected with a third-order individualized baseline management unit and a front stress recognition AI unit. And the third-order individualized baseline management unit and the front stress identification AI unit are respectively connected with the core correlation deduction AI unit. According to the method and system for monitoring the cardiac function rehabilitation state of the crowd after the coronary heart disease operation, dynamic baseline construction and the pathological evolution rule after the coronary heart disease operation are deeply bound, and the problem of high false alarm of a traditional fixed baseline in the early stage of the operation is thoroughly solved through triple-stage design and a dual calibration mechanism.

A method for assisting a heart ventricle can comprise providing a longitudinally expandable member that is reversibly expandable along a longitudinal dimension, wherein the longitudinally expandable member can include adjacent abutting portions meeting at respective bends that form acute angles along the longitudinal dimension. The method can include securing a first end portion of the longitudinally expandable member to a first wall portion of the heart ventricle via a first anchor engagement feature associated with the first end portion. The method can include securing a second end portion of the longitudinally expandable member to a second wall portion of the heart ventricle via a second anchor engagement feature associated with the second end portion, the plurality of bends between the first and second end portions allowing augmenting expansion of the heart ventricle using spring force of the longitudinally expandable member to thereby improve heart function.

Methods, systems, and devices for evaluating function of a heart are provided. The methods can include use of one or more imaging modalities to assess diastolic function. The methods, systems, and devices can employ various features of a cardiac volume curve to assess cardiac function. The methods, systems, and devices can be used to guide diagnosis, therapy, and / or training for sick or well patients. Methods, systems, and devices for assessing likelihood of hospital readmission for a heart failure patient are also provided.

Provided in the present application are a biomagnetic signal-based four-dimensional cardiac function imaging method and device. The method comprises: acquiring a cardiac magnetic signal of a subject to be tested and dynamic structure information of a target torso part within a full cardiac cycle, wherein the target torso part at least comprises two lungs, a torso, and a heart chamber and a pericardium structure thereof, and the dynamic structure information comprises a contour structure and a plurality of frames of dynamic images; performing spatial registration on the dynamic structure information and a sensor acquiring the cardiac magnetic signal to obtain coordinates of the sensor in a coordinate system of the dynamic structure information; calculating and reconstructing a cardiac electrical excitation activity based on the dynamic structure information, the coordinates of the sensor, and the cardiac magnetic signal to obtain a calculation and reconstruction result; and converting the calculation and reconstruction result into a four-dimensional visualization image.

An assessment of basal cardiac fitness uses noninvasively obtained physiological measures to determine the presence of a basal physiological state and cardiometric measures to determine cardiac fitness. In the presence of preload independence and cardiac vagal control, cardiometric signals are acquired that are sensitive to cardiac function and include information indicative of the opening and closing of the individual's aortic valve. The cardiometric signals are analyzed by a cardiac fitness assessment system for the determination of basal cardiac fitness. The invention assures preload independence through the assessment of observational physiological parameters or the use of physiological parameters obtained following alterations in venous return. The invention assures the presence of cardiac vagal control by assessment of measured parameters, including the presence of respiratory sinus arrhythmia. The resulting test is specific for cardiac function without dependencies on physical activities associated with heart rate elevation or respiratory capabilities.

The utility model relates to the technical field of medical instruments, in particular to a pacemaker electrode wire, which comprises a wire conduit, the wire conduit comprises a head part and a tail part which are connected with each other, the head part is provided with an electrode assembly, and the electrode assembly comprises a first electrode and a second electrode which are electrically connected with each other. The first electrode and the second electrode are arranged in a spaced mode in the direction from the head to the tail, and a fixing piece located between the first electrode and the second electrode is arranged on the outer side of the wire conduit. The head of the wire conduit can be sent to the right ventricular apex of the heart of a patient through vein puncture, and the fixing piece is in contact with and fixed to the surface of the endocardium, so that the first electrode is firmly fixed to the right ventricular apex, the electrode wire is kept stable in the heart of the patient, and the electrode wire is prevented from shifting or falling off; and the normal cardiac function of the patient is ensured.

A wearable device (100) for monitoring cardiac function during apnoeic episode. Wearable device including ballistocardiography (BCG) sensor (102A) to measure mechanical forces generated by heart and respiratory movement; electrocardiography (ECG) sensor (102B) to measure electrical activity of heart; and processor (102C) operatively connected to BCG sensor and ECG sensor to generate BCG data from measured mechanical forces and ECG data from measured electrical activity, respectively. Processor configured to: filter respiratory signals and heart signals from BCG data; detect apnoeic episode based on low respiratory signals or absence of respiratory signals for predetermined time period in filtered BCG data; determine compensatory mechanical output of heart using at least one of filtered BCG data or ECG data for apnoeic episode, and predict risk of cardiac condition based on compensatory mechanical output during apnoeic episode. Also a system (300) and method thereof.

The present disclosure relates treating skeletal muscle weakness associated with heart failure by administering a compound that binds to leaky ryanodine receptors (RyRs). Compounds of the present disclosure can bind to and repair the leak in both RyR1 and RyR2 to improve skeletal muscle and cardiac function, respectively.

This invention belongs to the field of pharmaceutical technology, specifically relating to the application of lemon balm glycosides in the preparation of drugs for the prevention or treatment of heatstroke. By constructing a mouse model of heatstroke-induced myocardial injury and observing indicators such as rectal temperature, blood routine tests, blood biochemistry, oxidative stress, and cardiac function, this invention found that lemon balm glycosides can significantly reduce the increase in rectal temperature caused by heatstroke in mice, increase the content of red blood cells and albumin in plasma, and reduce the level of oxidative stress in myocardial cells. Therefore, the application of lemon balm glycosides in the preparation of drugs for the prevention or treatment of heatstroke is proposed.

The invention discloses application of an HIF1A inhibitor in preparation of a medicine for preventing and / or treating hypertrophic cardiomyopathy, and belongs to the field of biological medicine. For a rat model of spontaneous hypertrophic cardiomyopathy caused by MYH7B gene knockout, hypertrophic cardiomyopathy can be significantly relieved by intraperitoneal injection of the HIF1A inhibitor LW6, heart remodeling can be relieved, heart functions can be improved, and myocardial hypertrophy caused by silent MYH7B genes can be effectively resisted by using siRNA of mRNA transcribed by the HIF1A gene. The key mechanism of the HIF1A inhibitor for treating the hypertrophic cardiomyopathy is that the hypertrophic cardiomyopathy is prevented and treated by reducing the expression level of glycolysis key enzymes GLUT1, HK2 and the like, inhibiting the formation and accumulation of cardiac lactic acid and improving the ventricular remodeling of the hypertrophic cardiomyopathy. The results show that the HIF1A inhibitor can be used for treating and / or preventing the human hypertrophic cardiomyopathy and has the potential of being developed into the medicine for clinically preventing and treating the hypertrophic cardiomyopathy.

The invention belongs to the technical field of biological medicines, and particularly provides a small molecule compound E229-0305 for preparing a medicine for treating myocardial fibrosis. The small molecule compound E229-0305 can target PTGS2 protein, inhibit fibrosis of myocardial fibroblasts induced by TGF-beta1, reduce proliferation and migration capabilities of the myocardial fibroblasts, inhibit the fibroblasts from being converted into myofibroblasts, and inhibit expression of fibrosis-related genes and proteins. Besides, in a model of myocardial fibrosis after myocardial infarction of a mouse, the small molecule compound E229-0305 improves the cardiac function of the mouse with myocardial infarction and reduces the fibrosis area and collagen deposition of the heart. The small molecule compound E229-0305 can be used as a brand-new targeted PTGS2 small molecule inhibitor for preparing medicines for preventing and treating myocardial fibrosis.

Systems and methods and devices are provided for treating conditions such as heart failure and / or pulmonary hypertension by at least partially occluding flow through the superior vena cava for an interval spanning multiple cardiac cycles. A catheter with an occlusion device is provided along with a controller that actuates a drive mechanism to provide at least partial occlusion of the patient's superior vena cava, which reduces cardiac filling pressures, and induces a favorable shift in the patient's Frank-Starling curve towards healthy heart functionality and improved cardiac performance. The occlusion device may include a lumen obstructed by a relief valve that may permit fluid flow through the occlusion device to release an excessive build-up of pressure.

Cardiomyopathies are heart muscle disorders which represent a heterogeneous group of diseases that often lead to progressive heart failure with significant morbidity and mortality. Here, the inventors show that neutralization of acyl CoA binding protein (ACBP) / diazepam binding inhibitor (DBI) reduces the deleterious effect of the Vehicle anthracycline doxombicin on cardiac function. Since anthracycline-induced heart failure and anthracycline-induced senescence are models of accelerated cardiac aging, it is also plausible to use ACBP / DBI inhibition or neutralization as a method to prevent or treat aging of the cardiovascular system. The inventors also found that genetic and pharmacological interventions to deplete ACBP / DBI efficiently improves cardiac dysfunction associated with experimental HFpEF, a condition associated with aging, hypertension and obesity. Accordingly, the present disclosure relates to methods for the treatment of cardiac dysfunction comprising neutralization of ACBP / DBI.

The invention relates to the technical field of traditional Chinese medicine preparations, in particular to an anti-heart-failure traditional Chinese medicine composition and a pharmaceutical preparation. The traditional Chinese medicine composition comprises sun-dried ginseng, radix ophiopogonis, schisandra chinensis, American ginseng, pseudo-ginseng and poria cocos. The traditional Chinese medicine composition for resisting heart failure and the medicinal preparation provided by the invention can relieve myocardial damage and load of patients with heart failure and relieve myocardial hypertrophy and fibrosis, so that the heart function of the patients with heart failure is effectively improved.

The invention relates to the technical field of evaluation of heart rehabilitation curative effects of breast cancer chemotherapy patients, in particular to a method and system for evaluating the heart rehabilitation curative effects of the breast cancer chemotherapy patients, and the method comprises the following steps: continuously obtaining heart rate variability data and skin conductance data of the breast cancer chemotherapy patients; based on the heart rate variability data and the skin conductance data, the activation state of the autonomic nervous system of the patient is judged; according to the activation state of the autonomic nervous system of the patient, quantifying the intensity and duration of the internal emotional state of the patient, and generating an emotional energy index; when the conventional physiological indexes of the patient fluctuate, determining a physiological fluctuation attribution result in combination with the emotional energy index to distinguish whether the physiological fluctuation is derived from heart function change or emotional influence; and evaluating the cardiac rehabilitation effect of the patient based on the physiological fluctuation attribution result. The accuracy of heart rehabilitation curative effect evaluation can be improved.

The invention relates to the field of traditional Chinese medicines, in particular to a preparation method of an Anqi flat-pressing capsule which comprises the following components in parts by weight: 6-7 parts of astragalus membranaceus, 6-7 parts of codonopsis pilosula, 4g of salvia miltiorrhiza, 5-6 parts of cortex moutan, 5-6 parts of malt, 5-6 parts of hawthorn, 3-4 parts of scutellaria baicalensis, 3-4 parts of radix bupleuri, 2.5 g of diazepam, 1-2 parts of nimodipine and 2-3 parts of radix isatidis. The capsule has the effects of nourishing heart, stabilizing mind, promoting blood circulation to remove blood stasis, soothing liver-qi stagnation, dredging and regulating internal organs, regulating qi activity, reducing heart pressure, maintaining normal functions of the heart, enabling qi and blood to be smooth and smooth, coordinating functions of the internal organs, reducing resistance and reducing blood pressure, so that the heart is protected against mind, and the main mind is relieved if the main mind is relieved. The capsule has the advantages of normal heart function, reduced pressure, relatively stable blood pressure, smooth qi and blood, healthy body and no occurrence of diseases, can be used for treating various hypertension and intractable hypertension diseases, and has no side effect.

The invention provides application of ML324 in preparation of drugs for treating and / or preventing heart diseases. The invention shows that the ML324 can prevent and / or treat heart diseases related to myocardial cell death, obviously inhibit activity decline of myocardial cells induced by a cell death inducer Erastin and H2O2, and improve the cell survival rate; generation of active oxygen in cells is reduced, and death modes such as myocardial cell apoptosis are reduced; the compound can be used for preventing, treating and improving heart function damage, myocardial fibrosis and heart organic damage caused by heart diseases, has a good application prospect in the aspect of developing medicines for resisting the heart diseases, and provides a new medicine research and development direction for preventing, treating and improving the heart diseases.

This invention discloses an intestinal fungus Saccharomyces cerevisiae M7015 and its applications belong to the field of microbial technology. Saccharomyces cerevisiae The accession number for M7015 is GDMCC No. 66195. This invention first demonstrated, using a mouse subcutaneous stroma embolism model, that the aforementioned strain can promote angiogenesis; secondly, using mouse and Bama miniature pig myocardial infarction models, it was found that the aforementioned strain can promote collateral angiogenesis in ischemic areas of the heart and improve cardiac function. This invention not only fully elucidates... Saccharomyces cerevisiae M7015 promotes the formation of collateral vessels in the heart and improves cardiac function, and also reveals the broad application prospects of this bacterium in the treatment of vascular diseases.

Provided is a health monitoring device that extracts, in particular, an apical beat component from a trunk acoustic pulse wave and thus is also usable in the medical field. The health monitoring device (1000) of the present invention analyzes a trunk acoustic pulse wave to estimate the health condition of a person using a correlation of an indicator relating to a left ventricular pressure waveform which indicates the behavior of the heart, with a vibration frequency of a frequency component stemming from an apical beat, a diastolic time interval in a cardiac cycle, or blood pressure. The former is input information and the latter is output information of the heart through which blood circulates, and thus comparing these two pieces of information makes it possible to know a health condition relating to the function of the heart more accurately than conventionally.

The present invention relates to systems, methods and algorithms for determination of heart pump function and their use in livings subject are described.The invention further relates to complementary parts of such systems that work best in combination.Medical catheters, sheaths and shafts are disclosed that carry an arrangement of integrated digital sensor systems-on-chip (SoC) in the portion thereof residing inside the body. These devices combine at their portion that resides inside the body, the complete chain of signal transduction, signal analog-to-digital conversion and digital signal transmission, and allow to acquire single and multiple physical entities in a single setup. In specific instances the devices integrate wireless data transfer functionality, and in specific instances they integrate wireless energy harvesting for battery-free functionality.The present invention further describes complementary monitor systems that are suited for reception, processing and analysis of data acquired by such catheters / sheaths / shafts to yield a robust assessment of cardiac performance.Moreover, the present invention relates to innovations which render such systems applicable to patients with and without cardiac assist devices.

The invention provides an intelligent data analysis method for a pension information service system, relates to the technical field of physiological data processing, and aims to judge behavior stages according to the daily moving speed of the elderly and the continuity of the speed in time, select stable effective behavior stages through deterministic scores, and improve the accuracy of the behavior stages. Judging a corresponding behavior state according to the change characteristic of the heart rate in the effective behavior stage, identifying the body function expression of the old person in the corresponding state according to the change rate characteristic of the central rate of each behavior state, and judging the reaction intensity in the first behavior state and the flat intensity in the second behavior state; and a heart function change index is constructed by combining the long-term comprehensive expression of the reaction intensity, the flat intensity and the heart rate in the third behavior state, so that the overall body function change characteristics are reflected and quantified, and a guardian can conveniently know the overall body condition change of the old.

The invention provides an immunosuppressive dendritic cell as well as a preparation method and application of the immunosuppressive dendritic cell, and belongs to the technical field of cell drugs. According to the dendritic cell of the over-expression CP-IL10-CAR fusion protein, CTLA4-Ig, PD-L1 and IL-10 with the amino acid sequences shown in SEQ ID NO: 17-19 are over-expressed in the dendritic cell, and a chimeric antigen receptor of a targeted fibroblast activation protein alpha (FAP) positive cell shown in SEQ ID NO: 20 is further expressed on the surface of the dendritic cell. The CP-IL10-CAR-dendritic cell medicine can be used for remarkably reducing the expression level of cardiac tissue fibrosis related protein caused by myocardial infarction, aortic arch constriction and myocardial ischemia reperfusion, regulating and controlling secretion of inflammatory factors, relieving the cardiac fibrosis degree and improving the cardiac function, and the dosage is small. Therefore, the invention provides a new means for preventing and treating heart fibrosis related diseases.

Systems and methods are provided for treating conditions such as heart failure and / or pulmonary hypertension by at least partially occluding flow through the superior vena cava for an interval spanning multiple cardiac cycles. A catheter with an occlusion device is provided along with a controller that actuates a drive mechanism to provide at least partial occlusion of the patient's superior vena cava, which reduces cardiac filling pressures, and induces a favorable shift in the patient's Frank-Starling curve towards healthy heart functionality and improved cardiac performance. The system may include sensors to determine the degree of occlusion of the superior vena cava. The occlusion system may be used to reduce volume in a heart and facilitate a cardiac procedure. The occlusion system may be used to relieve an overloaded chamber during and / or after deploying a VAD.

A blood pump (1) for patient heart support comprises a flow cannula (4) with a distal end (10) and a proximal end (11) opposite the distal end (10). The distal end (10) of the flow cannula (4) is configured to connect to the patient's heart or a blood vessel, thereby establishing fluid communication between the blood pump (1) and the patient's heart and blood vessel, respectively. The flow cannula (4) comprises a distal portion (5) with said distal end (10) and a proximal portion (6) with said proximal end (11). Furthermore, the flow cannula (4) comprises an intermediate portion (7) attached to the distal portion (5) and the proximal portion (6). The intermediate portion (7) is designed to be twisted with less force than the distal portion (5) and the proximal portion (6). The intermediate portion (7) is configured to be completely occluded by twisting.At least a portion of the intermediate portion (7), either alone or in combination with the distal portion (5), is adapted to be permanently attached to the patient's heart or a blood vessel.

The invention provides application of a sodium-glucose co-transporter 2 inhibitor in preparation of a medicine for preventing or treating senescence. In an aging animal model, it is found that the sodium-glucose co-transporter 2 inhibitor empagliflozin can improve heart aging, enhance heart functions caused by aging and increase the ejection fraction of left ventricle; meanwhile, the memory function caused by senescence can be improved, and the expression levels of senescence factors p16, p21 and p53 are improved. The sodium-glucose co-transporter 2 inhibitor empagliflozin has a prospect of being developed as an anti-aging drug.

Methods, devices, and systems for assessing the cardiovascular health of a patient are disclosed herein. In one instance, a method for evaluating a condition of a patient comprises collecting left ventricular global strain data from an echocardiogram of the patient, collecting blood pressure data from a blood pressure waveform generated by the patient's heart, matching the left ventricular global strain data and the blood pressure data with respect to time, and analyzing the time-matched strain data and blood pressure data to assess the condition of the patient.

A system and method for cardiovascular monitoring and reporting are disclosed. The system (CV monitoring system) includes a data analysis system and an in-ear biosensor system that preferably includes left and right earbuds. The earbuds include infrasound / vibration sensors that detect biosignals from the individual including signals associated with cardiovascular activity (CV signals). The analysis system calculates cardiovascular function measurements (CV function measurements) based upon the CV signals. The CV monitoring system uses machine learning to predict blood pressure (BP) measurements of the individual based upon the CV signals and the calculated CV function measurements. In an embodiment, the CV monitoring system includes an EKG detection system that detects EKG signals associated with heart function. The analysis system can calculate additional CV function measurements from the EKG signals to augment the CV function measurements calculated from the CV signals, and predict BP measurements using the full complement of CV function measurements.